Maria Isabel Chiu

This inventor holds 10 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Aveo Pharmaceuticals, Inc., Pd-1 Acquisition Group, LLC, Osi Pharmaceuticals, Inc.. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maria Isabel Chiu. Retrieved from https://idiyas.com/inventor/maria-isabel-chiu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 3)

% Patents Active = 80.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 11.5

ph-index = 3

Forward Citations = 24(Granted Patents)

Company Filing History:

7 out of 42

Aveo Pharmaceuticals, Inc.

patents

3 out of 3

Pd-1 Acquisition Group, LLC

patents

1 out of 118

Osi Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258391 - Anti-GDF-15 antibodies (2025-03-25),

2. 11725047 - Anti-GDF-15 antibodies (2023-08-15),

3. 11639385 - Anti-PD-1 antibodies (2023-05-02),

4. 10597444 - Anti-GDF15 antibodies (2020-03-24),

5. 10544217 - Anti-PD-1 antibodies (2020-01-28),

6. 10239942 - Anti-PD-1 antibodies (2019-03-26),

7. 9896730 - Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment (2018-02-20),

8. 9725505 - Methods of treatment using anti-GDF15 antibodies (2017-08-08),

9. 9175076 - Anti-GDF15 antibodies (2015-11-03),

10. 7556796 - Directed complementation (2009-07-07),

Title: Maria Isabel Chiu: Pioneering Innovations in Monoclonal Antibodies

Introduction

Maria Isabel Chiu is a prominent inventor based in Newton Centre, MA, whose groundbreaking work has led to the filing of 10 patents. Her inventions primarily focus on the development of monoclonal antibodies, a pivotal area in therapeutic treatments.

Latest Patents

Among her latest patents, Maria has disclosed innovative anti-GDF-15 antibodies. These monoclonal antibodies are designed to bind and inhibit the activity of human GDF15. They present potential treatment options for individuals experiencing body weight loss, including cachexia, which is often associated with the over-expression of this specific protein.

Career Highlights

Throughout her career, Maria has made significant contributions in the biotechnology field while working with companies such as Aveo Pharmaceuticals, Inc. and Pd-1 Acquisition Group, LLC. Her expertise and dedication have been crucial in advancing therapeutic solutions in the healthcare sector.

Collaborations

In her journey as an inventor, Maria has collaborated with talented professionals, including Lorena Lerner and Sandra Abbott. These partnerships have fostered a supportive network that has enhanced her innovative pursuits and contributed to the success of her projects.

Conclusion

Maria Isabel Chiu exemplifies the spirit of innovation in the realm of biotechnology. With her significant number of patents and contributions to the field of monoclonal antibodies, she continues to inspire aspiring inventors and researchers worldwide. Her ongoing work promises to have a lasting impact on treatments for conditions linked to GDF15.

Profile summary based on public USPTO records.